FAQ: Zevra Therapeutics' MIPLYFFA Data Presentation at ICIEM 2025
Summary
What is the main topic of this announcement?
Zevra Therapeutics will present four posters on MIPLYFFA (arimoclomol) at the International Congress of Inborn Errors of Metabolism (ICIEM) in September 2025, including new data on its mechanism of action, pediatric use, and efficacy in patients switching from miglustat.
What is MIPLYFFA and what condition does it treat?
MIPLYFFA (arimoclomol) is a therapy approved in the U.S. for the treatment of Niemann-Pick disease type C (NPC), a rare disease with limited treatment options.
When and where will these presentations take place?
The presentations will occur at the International Congress of Inborn Errors of Metabolism (ICIEM) held from September 2-6, 2025, in Kyoto, Japan.
Why is this presentation significant?
One of the posters earned a Best Poster award and will detail MIPLYFFA’s unique mechanism of action targeting NPC pathophysiology, while other presentations feature positive new data from pediatric studies and efficacy analyses in specific patient populations.
What specific new data will be presented?
The presentations will include data from a pediatric substudy in patients younger than two years old and a prespecified efficacy analysis in patients on miglustat who switched from placebo to MIPLYFFA.
Who is Zevra Therapeutics and what is their focus?
Zevra Therapeutics is a commercial-stage company focused on creating transformational therapies for rare diseases with limited or no treatment options, combining science, data and patient need to bring life-changing therapeutics to people living with rare diseases.
Where can I find more information about this announcement?
The full press release can be viewed at https://ibn.fm/XjkBY, and more information about Zevra Therapeutics is available at www.zevra.com.
What is the significance of the Best Poster award?
The Best Poster award (#BP-19) recognizes the quality and importance of the presentation detailing MIPLYFFA’s unique mechanism of action targeting Niemann-Pick disease type C pathophysiology.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 188081